These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21790298)

  • 1. Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a randomized, controlled, double-blind multicenter clinical crossover trial.
    Döpfner M; Ose C; Fischer R; Ammer R; Scherag A
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):445-54. PubMed ID: 21790298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
    Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
    Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
    Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Oehler KU; Linder M; Haessler F; Huss M; Warnke A; Schmidt M; Schulte-Markworth M; Sieder C; Klatt J; Tracik F
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):377-85. PubMed ID: 20973708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.
    Lopez F; Silva R; Pestreich L; Muniz R
    Paediatr Drugs; 2003; 5(8):545-55. PubMed ID: 12895137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
    BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Does a morning dose of Methylphenidate Retard reduce hyperkinetic symptoms in the afternoon?].
    Sinzig JK; Döpfner M; Plück J; Banaschewski T; Stephani U; Lehmkuhl G; Rothenberger A;
    Z Kinder Jugendpsychiatr Psychother; 2004 Nov; 32(4):225-33. PubMed ID: 15565893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.
    Döpfner M; Gerber WD; Banaschewski T; Breuer D; Freisleder FJ; Gerber-von Müller G; Günter M; Hässler F; Ose C; Rothenberger A; Schmeck K; Sinzig J; Stadler C; Uebel H; Lehmkuhl G
    Eur Child Adolesc Psychiatry; 2004; 13 Suppl 1():I93-101. PubMed ID: 15322960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
    Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G
    Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
    Silva R; Muniz R; McCague K; Childress A; Brams M; Mao A
    Psychopharmacol Bull; 2008; 41(1):19-33. PubMed ID: 18362868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder.
    Wilens TE; Boellner SW; López FA; Turnbow JM; Wigal SB; Childress AC; Abikoff HB; Manos MJ
    J Am Acad Child Adolesc Psychiatry; 2008 Jun; 47(6):700-708. PubMed ID: 18434918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
    Childress AC; Cutler AJ; Marraffino A; McDonnell MA; Turnbow JM; Brams M; DeSousa NJ; Incledon B; Sallee FR; Wigal SB
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):2-14. PubMed ID: 31464511
    [No Abstract]   [Full Text] [Related]  

  • 16. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
    Brams M; Muniz R; Childress A; Giblin J; Mao A; Turnbow J; Borrello M; McCague K; Lopez FA; Silva R
    CNS Drugs; 2008; 22(8):693-704. PubMed ID: 18601306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.
    Gormez V; Avery B; Mann H
    Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2345-9. PubMed ID: 24065228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.
    Maldonado R
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1001-14. PubMed ID: 23611637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.